Position in AZN
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$1,179,653,872
New position
Shares Held
5,981,411
first reported quarter
Ownership
0.386%
of shares outstanding
% of Portfolio
0.28%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 65.89237890524493.ToString("F0")%
Shared 0.ToString("F0")%
None 34.10762109475507.ToString("F0")%
Derivatives in AZN
reported options exposure · as of Mar 31, 2026CallValue
$31,387,760
CallShares
159,151
PutValue
$31,002,984
PutShares
157,200
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026UBS Group AG holds $15,459,459,109 across 21 Drug Manufacturers - General names. AZN ranks #5 (7.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
4,043,568 | $3,719,152,536 | |
| 2 | ABBV |
AbbVie Inc.
|
14,051,196 | $3,055,994,614 | |
| 3 | JNJ |
Johnson & Johnson
|
10,209,327 | $2,495,567,886 | |
| 4 | MRK |
Merck & Co., Inc.
|
13,933,630 | $1,676,076,347 | |
| 5 | AZN |
Astrazeneca PLC
This page
|
5,981,411 | $1,179,653,872 | |
| 6 | AMGN |
Amgen Inc
|
3,148,040 | $1,107,637,870 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
3,930,216 | $547,754,202 | |
| 8 | PFE |
Pfizer Inc
|
17,609,150 | $494,464,929 |
All Filings in AZN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $31,002,984 | 157,200 | Put | Defined | 2026-05-05 | |
| 2026-03-31 | $31,387,760 | 159,151 | Call | Defined | 2026-05-05 | |
| 2026-03-31 | $1,179,653,872 | 5,981,411 | Shares | Defined | 2026-05-05 | |
| No filing history on record for this holder in this stock. | ||||||